{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-009490","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.716374+00:00","generated_at":"2026-05-31T16:04:43.630091+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEL-SCI bias analysis confirms Multikine survival benefit; 5-year survival 73% vs 45% in target population","bullets":["Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.","Target population (no lymph node, low PD-L1): Multikine 5-year survival 73% vs 45% control; hazard ratio 0.35.","Company plans 212-patient confirmatory registration study with FDA agreement.","Entire Phase 3 study of 923 patients also showed no bias; CEO notes high confidence in repeating survival benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-009490","json":"https://secwatch.observer/filing/0001654954-24-009490.json","markdown":"https://secwatch.observer/filing/0001654954-24-009490.md","text":"https://secwatch.observer/filing/0001654954-24-009490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/0001654954-24-009490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:04:43.630091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}